Prevalence of Latent Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A South-East London Cohort Study

被引：0
|
作者：
Paine, Gabriel Wisenfeld [1 ]
Cox, Rosie [1 ]
Evans, Rosa [1 ]
Hudson, Jake [1 ]
Baker, Lucy [1 ]
Simpson, Thomas [1 ]
机构：
[1] Lewisham & Greenwich NHS Trust, Univ Hosp Lewisham, London, England
来源：
LUNG CANCER | 2025年 / 200卷
关键词：
D O I：
10.1016/j.lungcan.2025.108243
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
133
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.
    Jacob, Saya
    Quandt, Zoe
    Melisko, Michelle E.
    Majure, Melanie
    Chien, Amy Jo
    Blaes, Anne Hudson
    Heditsian, Diane
    Esserman, Laura
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Clinical features of immune checkpoint inhibitor-related pneumonitis in older patients with lung cancer receiving immune checkpoint inhibitors-based therapy: a retrospective study
    Jiafan Liu
    Dongmei Zhou
    Na Wu
    Jia Liu
    Xiaonan Wang
    BMC Geriatrics, 25 (1)
  • [43] Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: Antibiotics immune checkpoint inhibitors in advanced NSCLC
    Schett, Anne
    Rothschild, Sacha I.
    Curioni-Fontecedro, Alessandra
    Kraehenbuehl, Stephan
    Frueh, Martin
    Schmid, S.
    Driessen, Christoph
    Joerger, Markus
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (01) : 121 - 131
  • [44] Presence of NAFLD in Patients Receiving Immune Checkpoint Inhibitors Significantly Increases the Prevalence of Immune Medicated Hepatotoxicity
    Hamid, Osama
    Eltelbany, Ahmed
    Mohammed, Abdul
    Asaad, Imad
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S546 - S546
  • [45] Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area
    Stroh, Gregory R.
    Peikert, Tobias
    Escalante, Patricio
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (11) : 3105 - 3111
  • [46] Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL-17 inhibitors? A cohort study
    Shu, Dan
    Zhang, Zhuying
    Zhou, Eray Yihui
    Ma, Xuzhu
    Zhao, Yi
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [47] Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area
    Gregory R. Stroh
    Tobias Peikert
    Patricio Escalante
    Cancer Immunology, Immunotherapy, 2021, 70 : 3105 - 3111
  • [48] Improved treatment and survival for lung cancer patients in south-east Scotland
    Erridge, Sara C.
    Murray, Brian
    Price, Allan
    Ironside, Janet
    Little, Felicity
    Mackean, Melanie
    Walker, William
    Brewster, David H.
    Black, Roger
    Fergusson, Ron J.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (05) : 491 - 498
  • [49] Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
    Klebanov, Nikolai
    Pahalyants, Vartan
    Murphy, William S.
    Theodosakis, Nicholas
    Zubiri, Leyre
    Klevens, R. Monina
    Kwatra, Shawn G.
    Lilly, Evelyn
    Reynolds, Kerry L.
    Semenov, Yevgeniy R.
    ONCOLOGIST, 2021, 26 (05): : E898 - E901
  • [50] Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors
    Kavgaci, Gozde
    Guven, Deniz Can
    Kaygusuz, Yunus
    Karaca, Ece
    Dizdar, Omer
    Kilickap, Saadettin
    Aksoy, Sercan
    Erman, Mustafa
    Yalcin, Suayib
    SUPPORTIVE CARE IN CANCER, 2024, 32 (07)
12345